Long-Term Efficacy and Safety of Low-Dose Rituximab in Patients with Refractory Myasthenia Gravis

Rituximab Therapy in the Treatment of Juvenile Myasthenia Gravis: The French Experience

(2022) Agathe Molimard et al.   NEUROLOGY

Double Seropositive Myasthenia Gravis Successfully Treated With Rituximab

(2022) Vasiliki Zouvelou et al.   Journal of Clinical Neuromuscular Disease

AChRAb and MuSKAb double-seropositive myasthenia gravis: a distinct subtype?

(2021) Jieni Zhang et al.   NEUROLOGICAL SCIENCES

Efficacy of Low-Dose Rituximab on Neuromyelitis Optica-Associated Optic Neuritis

(2021) Shuo Zhao et al.   Frontiers in Neurology

A long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders

(2020) Qianshuo Lu et al.   Multiple Sclerosis and Related Disorders

Low‐dose rituximab every 6 months for the treatment of acetylcholine receptor–positive refractory generalized myasthenia gravis

(2019) Jun Lu et al.   MUSCLE & NERVE

Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study

(2018) Philippe Cabre et al.   JOURNAL OF NEUROLOGY

Long-term follow-up of patients with myasthenia gravis treated with low-dose rituximab

(2018) Fiona Chan et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis

(2017) Sisi Jing et al.   JOURNAL OF NEUROIMMUNOLOGY

Rituximab treatment of myasthenia gravis: A systematic review

(2017) Rup Tandan et al.   MUSCLE & NERVE

Resistant myasthenia gravis and rituximab: A monocentric retrospective study of 28 patients

(2017) Vadim Afanasiev et al.   NEUROMUSCULAR DISORDERS

Hypersensitivity and immunologic reactions to biologics: opportunities for the allergist

(2016) David A. Khan   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Suppression of normal immune responses after treatment with rituximab

(2016) Ruba Kado et al.   CURRENT OPINION IN RHEUMATOLOGY

Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis

(2015) Manjari Lahiri et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years

(2015) R. F. van Vollenhoven et al.   JOURNAL OF RHEUMATOLOGY

Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today?

(2015) F. M. McQueen et al.   RHEUMATOLOGY

A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis

(2013) James F. Howard et al.   MUSCLE & NERVE

Incidence of Hypogammaglobulinemia in Patients Receiving Rituximab and the Use of Intravenous Immunoglobulin for Recurrent Infections

(2012) Carla Casulo et al.   Clinical Lymphoma Myeloma & Leukemia

The MG Composite: A valid and reliable outcome measure for myasthenia gravis

(2010) T. M. Burns et al.   NEUROLOGY